Cited by 314Obsessive-Compulsive Spectrum DisordersAnxiety, Depression, Psychometrics, Treatment, Cognitive ProcessesPsychoanalysis and Psychopathology Research

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: An open-label trial

Coric, Vladimir, Taskiran, Sarper, Pittenger, Christopher, Wasylink, Suzanne, Mathalon, Daniel H., Valentine, Gerald, Saksa, John, Wu, Yu-te, Gueorguieva, Ralitza, Sanacora, Gerard, Malison, Robert T., Krystal, John H.·2005·Biological Psychiatry

DOI 10.1016/j.biopsych.2005.04.043

Open this paper in CoChat — free account

Abstract

Background Most patients with obsessive-compulsive disorder (OCD) show only partial reduction of symptoms with standard therapy. Recent imaging data suggests glutamatergic dysfunction in the corticostriatal pathway in OCD. We investigated the efficacy of augmentation therapy with riluzole, a glutamate-modulating agent, in treatment-resistant OCD.Methods Thirteen patients aged between 18 and 65 years with a primary diagnosis of OCD that had proven resistant to standard treatment were treated with the addition of riluzole to their existing pharmacotherapy. Yale-Brown Obsessive Compulsive Scale (Y-BOCS), Hamilton Depression Inventory (HAM-D), and Hamilton Anxiety Inventory (HAM-A) scores were obtained weekly.Results Thirteen treatment-resistant OCD patients received riluzole 50 mg twice a day. Y-BOCS scores improved significantly over time. Of 13 patients, 7 (54%) demonstrated a >35% reduction in Y-BOCS scores, and 5 (39%) were categorized as treatment responders. HAM-D and HAM-A scores for the group also significantly improved over time. Riluzole was well tolerated with no serious adverse effects noted.Conclusions Riluzole appears to have significant antiobsessional, antidepressant, and antianxiety properties. The addition of this agent may be of practical clinical benefit in patients with OCD.

Integrity signals

Registry

Crossref · 10.1016/j.biopsych.2005.04.043

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Applied Mixed Models in Medicine
Brown, H., & Presco, R. (2000) · Technometrics · doi:10.1080/00401706.2000.10485742 · Cited by 1,699
Move Over ANOVA: Progress in Analyzing Repeated-Measures Data andIts Reflection in Papers Published in the Archives of General Psychiatry
Gueorguieva, R., & Krystal, J. H. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.3.310 · Cited by 1,529
Energy on demand.
Magistretti, P. J., Pellerin, L., Rothman, D. L., & Shulman, R. G. (1999) · Science · doi:10.1126/science.283.5401.496 · Cited by 1,170
Subtype-Specific Alterations of γ-Aminobutyric Acid and Glutamatein Patients With Major Depression
Sanacora, G., Gueorguieva, R. V., Epperson, C. N., Wu, Y., Appel, M., Rothman, D. L., Krystal, J. H., & Mason, G. F. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.7.705 · Cited by 796
Reduced glutamate in the anterior cingulate cortex in depression: an in vivo proton magnetic resonance spectroscopy study
Auer, D. P., Pütz, B., Kraft, E., Lipinski, B., Schill, J., & Holsboer, F. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00159-6 · Cited by 562
Neurobiology of Mental Illness
(2011) · Oxford University Press eBooks · doi:10.1093/med/9780199798261.001.0001 · Cited by 523
Determination of the rate of the glutamate/glutamine cycle in the human brain by in vivo 13 C NMR
Shen, J., Petersen, K. F., Behar, K. L., Brown, P., Nixon, T. W., Mason, G. F., Petroff, O. A. C., Shulman, G. I., Shulman, R. G., & Rothman, D. L. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.14.8235 · Cited by 462
The Physicians' Desk Reference
Cohen, J. S. (1996) · Archives of Internal Medicine · doi:10.1001/archinte.1996.00440120021003 · Cited by 430
Riluzole inhibits the persistent sodium current in mammalian CNS neurons
Urbani, A., & Belluzzi, O. (2000) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2000.00242.x · Cited by 381
Decrease in Caudate Glutamatergic Concentrations in Pediatric Obsessive-Compulsive Disorder Patients Taking Paroxetine
ROSENBERG, D. R., MacMASTER, F. P., KESHAVAN, M. S., FITZGERALD, K. D., STEWART, C. M., & MOORE, G. J. (2000) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200009000-00008 · Cited by 377

Show all 25 references

Sorted by citations

Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
“Other agents that have been studied as adjunctive therapy for treatment-resistant OCD include celecoxib [777], granisetron [778], IV ketamine [779,780], ondansetron [784,785], N-acetylcysteine [786,787] (all Level 2), and riluzole (Level 3) [788,789].”
Background
Obsessive-compulsive disorder
Abramowitz, J. S., Taylor, S., & McKay, D. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60240-3 · Cited by 1,002
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision
Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H., & WFSBP Task Force on Treatment Guide (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 887
Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology
Baldwin, D. S., Anderson, I. M., Nutt, D. J., Allgulander, C., Bandelow, B., den Boer, J. A., Christmas, D. M., Davies, S., Fineberg, N., Lidbetter, N., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114525674 · Cited by 676
The role of glutamate transporters in neurodegenerative diseases and potential opportunities for intervention
Sheldon, A. L., & Robinson, M. B. (2007) · Neurochemistry International · doi:10.1016/j.neuint.2007.03.012 · Cited by 593
Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment
Pittenger, C., Bloch, M. H., & Williams, K. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.09.006 · Cited by 426
Randomized Controlled Crossover Trial of Ketamine in Obsessive-Compulsive Disorder: Proof-of-Concept
Rodriguez, C. I., Kegeles, L. S., Levinson, A., Feng, T., Marcus, S. M., Vermes, D., Flood, P., & Simpson, H. B. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.150 · Cited by 386
N-Acetylcysteine, a Glutamate Modulator, in the Treatment of Trichotillomania: A Double-blind, Placebo-Controlled Study
Grant, J. E., Odlaug, B. L., & Won Kim, S. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.60 · Cited by 424
Evidence-based pharmacotherapy of obsessive-compulsive disorder
Fineberg, N. A., Brown, A., Reghunandanan, S., & Pampaloni, I. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001829 · Cited by 336
Zinc‐Mediated Formation of Trifluoromethyl Ethers from Alcohols and Hypervalent Iodine Trifluoromethylation Reagents
Koller, R., Stanek, K., Stolz, D., Aardoom, R., Niedermann, K., & Togni, A. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200900974 · Cited by 314
N-Acetyl Cysteine, a Glutamate-Modulating Agent, in the Treatment of Pathological Gambling: A Pilot Study
Grant, J. E., Kim, S. W., & Odlaug, B. L. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.11.021 · Cited by 307
The role of glutamate signaling in the pathogenesis and treatment of obsessive-compulsive disorder
Wu, K., Hanna, G. L., Rosenberg, D. R., & Arnold, P. D. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.10.007 · Cited by 264
Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders
Sartori, S. B., & Singewald, N. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107402 · Cited by 236
The Role of Glutamate in Anxiety and Related Disorders
Cortese, B. M., & Phan, K. L. (2005) · CNS Spectrums · doi:10.1017/s1092852900010427 · Cited by 231
Glutamatergic Modulators: The Future of Treating Mood Disorders?
Zarate, C., Machado-Vieira, R., Henter, I., Ibrahim, L., Diazgranados, N., & Salvadore, G. (2010) · Harvard Review of Psychiatry · doi:10.3109/10673229.2010.511059 · Cited by 228
Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder
Pittenger, C., Krystal, J. H., & Coric, V. (2006) · NeuroRx · doi:10.1016/j.nurx.2005.12.006 · Cited by 225
Pharmacological Treatment of Obsessive-Compulsive Disorder
Pittenger, C., & Bloch, M. H. (2014) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2014.05.006 · Cited by 222
Self-citation
Sapap3 and pathological grooming in humans: Results from the OCD collaborative genetics study
Bienvenu, O. J., Wang, Y., Shugart, Y. Y., Welch, J. M., Grados, M. A., Fyer, A. J., Rauch, S. L., McCracken, J. T., Rasmussen, S. A., Murphy, D. L., et al. (2009) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30897 · Cited by 207
Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials
Dold, M., Aigner, M., Lanzenberger, R., & Kasper, S. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000740 · Cited by 211
New perspectives in glutamate and anxiety
Riaza Bermudo-Soriano, C., Perez-Rodriguez, M. M., Vaquero-Lorenzo, C., & Baca-Garcia, E. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.04.010 · Cited by 207
N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder
Lafleur, D. L., Pittenger, C., Kelmendi, B., Gardner, T., Wasylink, S., Malison, R. T., Sanacora, G., Krystal, J. H., & Coric, V. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0246-6 · Cited by 200
An Open-Label Trial of Riluzole, a Glutamate Antagonist, in Children with Treatment-Resistant Obsessive-Compulsive Disorder
Grant, P., Lougee, L., Hirschtritt, M., & Swedo, S. E. (2007) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2007.0021 · Cited by 197
Association of the SLC1A1 glutamate transporter gene and obsessive‐compulsive disorder
Stewart, S. E., Fagerness, J. A., Platko, J., Smoller, J. W., Scharf, J. M., Illmann, C., Jenike, E., Chabane, N., Leboyer, M., Delorme, R., et al. (2007) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30533 · Cited by 182
Pharmacological treatment of anxiety disorders: Current treatments and future directions
Farach, F. J., Pruitt, L. D., Jun, J. J., Jerud, A. B., Zoellner, L. A., & Roy‐Byrne, P. (2012) · Journal of Anxiety Disorders · doi:10.1016/j.janxdis.2012.07.009 · Cited by 202
Riluzole in the Treatment of Mood and Anxiety Disorders
Pittenger, C., Coric, V., Banasr, M., Bloch, M., Krystal, J. H., & Sanacora, G. (2008) · CNS Drugs · doi:10.2165/00023210-200822090-00004 · Cited by 177
Anti-Brain Autoantibodies and Altered Excitatory Neurotransmitters in Obsessive–Compulsive Disorder
Bhattacharyya, S., Khanna, S., Chakrabarty, K., Mahadevan, A., Christopher, R., & Shankar, S. K. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.77 · Cited by 172
The Role of the Tripartite Glutamatergic Synapse in the Pathophysiology and Therapeutics of Mood Disorders
Machado-Vieira, R., Manji, H. K., & Zarate, C. A. (2009) · The Neuroscientist · doi:10.1177/1073858409336093 · Cited by 171
Effects of Ketamine in Treatment-Refractory Obsessive-Compulsive Disorder
Bloch, M. H., Wasylink, S., Landeros-Weisenberger, A., Panza, K. E., Billingslea, E., Leckman, J. F., Krystal, J. H., Bhagwagar, Z., Sanacora, G., & Pittenger, C. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.05.028 · Cited by 162
Clinical advances in obsessive-compulsive disorder: a position statement by the International College of Obsessive-Compulsive Spectrum Disorders
Fineberg, N. A., Hollander, E., Pallanti, S., Walitza, S., Grünblatt, E., Dell’Osso, B. M., Albert, U., Geller, D. A., Brakoulias, V., Janardhan Reddy, Y. C., et al. (2020) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000314 · Cited by 161
Animal models of obsessive-compulsive disorder: Exploring pharmacology and neural substrates
Albelda, N., & Joel, D. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2011.04.006 · Cited by 165
A Single-Blinded Case-Control Study of Memantine in Severe Obsessive-Compulsive Disorder
Stewart, S. E., Jenike, E. A., Hezel, D. M., Stack, D. E., Dodman, N. H., Shuster, L., & Jenike, M. A. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181c856de · Cited by 158
Memantine add-on in moderate to severe obsessive-compulsive disorder: Randomized double-blind placebo-controlled study
Ghaleiha, A., Entezari, N., Modabbernia, A., Najand, B., Askari, N., Tabrizi, M., Ashrafi, M., Hajiaghaee, R., & Akhondzadeh, S. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2012.09.015 · Cited by 152
Obsessive-compulsive disorder (OCD): practical strategies for pharmacological and somatic treatment in adults
Fineberg, N. A., Reghunandanan, S., Simpson, H. B., Phillips, K. A., Richter, M. A., Matthews, K., Stein, D. J., Sareen, J., Brown, A., & Sookman, D. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2014.12.003 · Cited by 150
Drug treatment of obsessive-compulsive disorder
Kellner, M. B. (2010) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2010.12.2/mkellner · Cited by 150
Memantine Augmentation in Treatment-Resistant Obsessive-Compulsive Disorder
Aboujaoude, E. N., Barry, J. J., & Gamel, N. N. (2009) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318192e9a4 · Cited by 138
Double-Blind, Placebo-Controlled Trial of Topiramate Augmentation in Treatment-Resistant Obsessive-Compulsive Disorder
Berlin, H. A., Koran, L. M., Jenike, M. A., Shapira, N. A., Chaplin, W. F., Pallanti, S., & Hollander, E. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05266gre · Cited by 129
Glutamatergic Synaptic Dysfunction and Obsessive-Compulsive Disorder
Ting, J. T., & Feng, G. (2008) · Current Chemical Genomics · doi:10.2174/1875397300802010062 · Cited by 125
Neuronal Correlates of Obsessions in the Caudate Nucleus
Guehl, D., Benazzouz, A., Aouizerate, B., Cuny, E., Rotgé, J., Rougier, A., Tignol, J., Bioulac, B. H., & Burbaud, P. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.06.023 · Cited by 124
Unmet need for services and interventions among adolescents with mental disorders
Wang, P. S., Sherrill, J., & Vitiello, B. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.1.1 · Cited by 123
Pharmacotherapy of obsessive–compulsive disorder: evidence-based treatment and beyond
Fineberg, N. A., Reghunandanan, S., Brown, A., & Pampaloni, I. (2013) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867412461958 · Cited by 122
Comorbid obsessive-compulsive symptoms in schizophrenia: contributions of pharmacological and genetic factors
Schirmbeck, F. N., & Zink, M. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00099 · Cited by 125
Children with obsessive-compulsive disorder: are they just “little adults”?
Kalra, S. K., & Swedo, S. E. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37563 · Cited by 114
Zinc‐Mediated Formation of Trifluoromethyl Ethers from Alcohols and Hypervalent Iodine Trifluoromethylation Reagents
Koller, R., Stanek, K., Stolz, D., Aardoom, R., Niedermann, K., & Togni, A. (2009) · Angewandte Chemie · doi:10.1002/ange.200900974 · Cited by 110
N-acetylcysteine augmentation therapy for moderate-to-severe obsessive-compulsive disorder: randomized, double-blind, placebo-controlled trial
Paydary, K., Akamaloo, A., Ahmadipour, A., Pishgar, F., Emamzadehfard, S., & Akhondzadeh, S. (2016) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12370 · Cited by 106
Anxiety and affective disorder comorbidity related to serotonin and other neurotransmitter systems: obsessive–compulsive disorder as an example of overlapping clinical and genetic heterogeneity
Murphy, D. L., Moya, P. R., Fox, M. A., Rubenstein, L. M., Wendland, J. R., & Timpano, K. R. (2013) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2012.0435 · Cited by 112
Meta‐analysis of association between obsessive‐compulsive disorder and the 3′ region of neuronal glutamate transporter gene SLC1A1
Stewart, S. E., Mayerfeld, C., Arnold, P. D., Crane, J. R., O'Dushlaine, C., Fagerness, J. A., Yu, D., Scharf, J. M., Chan, E., Kassam, F., et al. (2013) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32137 · Cited by 102
Assessment and Management of Treatment-Refractory Obsessive-Compulsive Disorder in Children
Bloch, M. H., & Storch, E. A. (2015) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2015.01.011 · Cited by 110
A systematic review of off-label uses of memantine for psychiatric disorders
Zdanys, K. F., & Tampi, R. R. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2008.01.008 · Cited by 105
Riluzole in psychiatry: a systematic review of the literature
Zarate, C. A., & Manji, H. K. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.9.1223 · Cited by 103
Obsessive Compulsive Disorder
Abramowitz, J. S., Mahaffey, B. L., & Wheaton, M. G. (2008) · Springer eBooks · doi:10.1002/9780470479216.corpsy0617 · Cited by 110
Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive–compulsive disorder: a double-blind, placebo-controlled study
Bruno, A., Micò, U., Pandolfo, G., Mallamace, D., Abenavoli, E., Di Nardo, F., D’Arrigo, C., Spina, E., Zoccali, R. A., & Muscatello, M. R. A. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881111431751 · Cited by 103
Pharmacotherapy augmentation strategies in treatment-resistant anxiety disorders
Ipser, J., Carey, P. D., Dhansay, Y., Fakier, N., Seedat, S., & Stein, D. J. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005473.pub2 · Cited by 103
Serotoninergic mechanisms in the treatment of obsessive–compulsive disorder
Goddard, A. W., Shekhar, A., Whiteman, A. F., & McDougle, C. J. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2007.12.009 · Cited by 112
Effects of glutamate-related drugs on marble-burying behavior in mice: Implications for obsessive–compulsive disorder
Egashira, N., Okuno, R., Harada, S., Matsushita, M., Mishima, K., Iwasaki, K., Nishimura, R., Oishi, R., & Fujiwara, M. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.01.035 · Cited by 95
LONG-TERM OUTCOME IN ADULTS WITH OBSESSIVE-COMPULSIVE DISORDER: Research Article: Long-Term Outcome in Adult OCD
Bloch, M. H., Green, C., Kichuk, S. A., Dombrowski, P. A., Wasylink, S., Billingslea, E., Landeros-Weisenberger, A., Kelmendi, B., Goodman, W. K., Leckman, J. F., et al. (2013) · Depression and Anxiety · doi:10.1002/da.22103 · Cited by 94
Self-citation
N-Acetyl Cysteine in the Treatment of Grooming Disorders
Odlaug, B. L., & Grant, J. E. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000264976.86990.00 · Cited by 94
Novel glutamatergic agents for major depressive disorder and bipolar disorder
Machado-Vieira, R., Ibrahim, L., Henter, I. D., & Zarate, C. A. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.09.010 · Cited by 92
Targeting glial physiology and glutamate cycling in the treatment of depression
Valentine, G. W., & Sanacora, G. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.04.008 · Cited by 87
Metabotropic and ionotropic glutamate receptors as neurobiological targets in anxiety and stress-related disorders: Focus on pharmacology and preclinical translational models
Harvey, B. H., & Shahid, M. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.06.014 · Cited by 90
Treatment-resistant OCD: Pharmacotherapies in adults
van Roessel, P., Grassi, G., Aboujaoude, E. N., Menchón, J. M., Ameringen, M. V., & Rodríguez, C. I. (2022) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2022.152352 · Cited by 103
A Double-Blind, Placebo-Controlled Trial of Lamotrigine for Pathological Skin Picking
Grant, J. E., Odlaug, B. L., Chamberlain, S. R., & Kim, S. W. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181e617a1 · Cited by 89
Review of the Use of the Glutamate Antagonist Riluzole in Psychiatric Disorders and a Description of Recent Use in Childhood Obsessive-Compulsive Disorder
Grant, P., Song, J. Y., & Swedo, S. E. (2010) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2010.0009 · Cited by 84
Motor control, habits, complex motor stereotypies, and Tourette syndrome
Singer, H. S. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12281 · Cited by 85
History of Psychosurgery: A Psychiatrist's Perspective
Lapidus, K. A. B., Kopell, B. H., Ben‐Haim, S., Rezai, A. R., & Goodman, W. K. (2013) · World Neurosurgery · doi:10.1016/j.wneu.2013.02.053 · Cited by 87
Animal models of obsessive–compulsive disorder: utility and limitations
Alonso, P., López‐Solà, C., Real, E., Segalàs, C., & Menchón, J. M. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s62785 · Cited by 88
Glutamate-Modulating Drugs as a Potential Therapeutic Strategy in Obsessive-Compulsive Disorder
Marinova, Z., Chuang, D.-M., & Fineberg, N. (2017) · Current Neuropharmacology · doi:10.2174/1570159x15666170320104237 · Cited by 83
Riluzole Augmentation in Treatment-Refractory Obsessive-Compulsive Disorder
Pittenger, C., Kelmendi, B., Wasylink, S., Bloch, M. H., & Coric, V. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181727548 · Cited by 83
Current animal models of obsessive compulsive disorder: an update
Albelda, N., & Joel, D. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.08.070 · Cited by 85
Obsessive compulsive disorder and the glutamatergic system
Kariuki, C. M., Gomez‐Mancilla, B., & Stein, D. J. (2013) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000017 · Cited by 82
Adjunctive glycine in the treatment of obsessive-compulsive disorder in adults
Greenberg, W. M., Benedict, M. M., Doerfer, J., Perrin, M., Panek, L., Cleveland, W. L., & Javitt, D. C. (2009) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2008.10.007 · Cited by 80
Regioselective Synthesis of N‐Heteroaromatic Trifluoromethoxy Compounds by Direct O−CF3 Bond Formation
Liang, A., Han, S., Liu, Z., Wang, L., Li, J., Zou, D., Wu, Y., & Wu, Y. (2016) · Chemistry - A European Journal · doi:10.1002/chem.201505181 · Cited by 80
Riluzole Augmentation in Treatment-Refractory Obsessive-Compulsive Disorder: A Pilot Randomized Placebo-Controlled Trial
Pittenger, C., Bloch, M. H., Wasylink, S., Billingslea, E., Simpson, R., Jakubovski, E., Kelmendi, B., Sanacora, G., & Coric, V. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09123 · Cited by 80
Marble-burying behavior test as a murine model of compulsive-like behavior
Dixit, P. V., Sahu, R. A., & Mishra, D. K. (2020) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2020.106676 · Cited by 87
BRAIN IMAGING IN PEDIATRIC OBSESSIVE COMPULSIVE DISORDER
Macmaster, F., O'Neill, J., & Rosenberg, D. (2008) · Journal of the American Academy of Child and Adolescent Psychiatry · doi:10.1097/chi.0b013e318185d2be · Cited by 77
Obsessive–Compulsive Disorder
Bokor, G., & Anderson, P. D. (2014) · Journal of Pharmacy Practice · doi:10.1177/0897190014521996 · Cited by 79
Augmentation strategies in obsessive–compulsive disorder
Arumugham, S. S., & Reddy, J. Y. C. (2013) · Expert Review of Neurotherapeutics · doi:10.1586/ern.12.160 · Cited by 78
Glutamatergic modulatory therapy for Tourette syndrome
Singer, H. S., Morris, C. M., & Grados, M. A. (2009) · Medical Hypotheses · doi:10.1016/j.mehy.2009.11.028 · Cited by 74
Investigating the Role of Glutamate in Obsessive-Compulsive Disorder: Current Perspectives
Karthik, S., Sharma, L. P., & Narayanaswamy, J. C. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s211703 · Cited by 78
Psychopharmacological Interventions in Autism Spectrum Disorder
Politte, L. C., Henry, C. A., & McDougle, C. J. (2014) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000030 · Cited by 75
Pharmacological treatment strategies in obsessive compulsive disorder: A cross-sectional view in nine international OCD centers
Van Ameringen, M., Simpson, W., Patterson, B., Dell’Osso, B., Fineberg, N., Hollander, E., Hranov, L., Hranov, G., Lochner, C., Karamustafalioglu, O., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881113517955 · Cited by 65
Minocycline combination therapy with fluvoxamine in moderate‐to‐severe obsessive–compulsive disorder: A placebo‐controlled, double‐blind, randomized trial
Esalatmanesh, S., Abrishami, Z., Zeinoddini, A., Rahiminejad, F., Sadeghi, M., Najarzadegan, M., Shalbafan, M., & Akhondzadeh, S. (2016) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12430 · Cited by 65
Open-label riluzole in fragile X syndrome
Erickson, C. A., Weng, N., Weiler, I. J., Greenough, W. T., Stigler, K. A., Wink, L. K., & McDougle, C. J. (2010) · Brain Research · doi:10.1016/j.brainres.2010.10.108 · Cited by 67
Drug Treatment of Trichotillomania (Hair-Pulling Disorder), Excoriation (Skin-picking) Disorder, and Nail-biting (Onychophagia)
Sani, G., Gualtieri, I., Paolini, M., Bonanni, L., Spinazzola, E., Maggiora, M., Pinzone, V., Brugnoli, R., Angeletti, G., Girardi, P., et al. (2019) · Current Neuropharmacology · doi:10.2174/1570159x17666190320164223 · Cited by 50
Neuromodulation for obsessive-compulsive disorder
Lapidus, K. A. B., Stern, E. R., Berlin, H. A., & Goodman, W. K. (2014) · Neurotherapeutics · doi:10.1007/s13311-014-0287-9 · Cited by 63
Memantine in the treatment of binge eating disorder: An open‐label, prospective trial
Brennan, B. P., Roberts, J. L., Fogarty, K. V., Reynolds, K. A., Jonas, J. M., & Hudson, J. I. (2008) · International Journal of Eating Disorders · doi:10.1002/eat.20541 · Cited by 64
Glutamatergic agents for OCD and related disorders
Pittenger, C. (2015) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-015-0051-8 · Cited by 62
Intravenous Ketamine “Burst” for Refractory Depression in a Patient with Advanced Cancer
Stefanczyk-Sapieha, L., Oneschuk, D., & Demas, M. (2008) · Journal of Palliative Medicine · doi:10.1089/jpm.2008.9828 · Cited by 61
A systematic review and meta-analysis: Memantine augmentation in moderate to severe obsessive-compulsive disorder
Modarresi, A., Chaibakhsh, S., Koulaeinejad, N., & Koupaei, S. R. (2019) · Psychiatry Research · doi:10.1016/j.psychres.2019.112602 · Cited by 63
The glutamate-based genetic immune hypothesis in obsessive-compulsive disorder. An integrative approach from genes to symptoms
Rotgé, J., Aouizerate, B., Tignol, J.-P., Bioulac, B. H., Burbaud, P., & Guehl, D. (2009) · Neuroscience · doi:10.1016/j.neuroscience.2009.10.043 · Cited by 63
Rapid Resolution of Obsessions After an Infusion of Intravenous Ketamine in a Patient With Treatment-Resistant Obsessive-Compulsive Disorder
Rodriguez, C. I., Kegeles, L. S., Flood, P., & Simpson, H. B. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10l06653 · Cited by 59
Pharmacological Treatment of Obsessive-Compulsive Disorder
Simpson, H. B. (2009) · Current topics in behavioral neurosciences · doi:10.1007/7854_2009_12 · Cited by 59
Issues in the pharmacological treatment of obsessive-compulsive disorder
Math, S. B., & Reddy, Y. C. J. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01356.x · Cited by 59
Minocycline Augmentation of Pharmacotherapy in Obsessive-Compulsive Disorder
Rodríguez, C. I., Bender, J., Marcus, S. M., Snape, M. F., Rynn, M. A., & Simpson, H. B. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09l05805blu · Cited by 56
Memantine as an Augmenting Agent for Severe Pediatric OCD
HEZEL, D. M., BEATTIE, K., & STEWART, S. E. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08091427 · Cited by 55
Riluzole in augmentation of fluvoxamine for moderate to severe obsessive–compulsive disorder: R andomized, double‐blind, placebo‐controlled study
Emamzadehfard, S., Kamaloo, A., Paydary, K., Ahmadipour, A., Zeinoddini, A., Ghaleiha, A., Mohammadinejad, P., Zeinoddini, A., & Akhondzadeh, S. (2016) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12394 · Cited by 56
Memantine Augmentation Improves Symptoms in Serotonin Reuptake Inhibitor-Refractory Obsessive-Compulsive Disorder: A Randomized Controlled Trial
Modarresi, A., Sayyah, M., Razooghi, S., Eslami, K., Javadi, M., & Kouti, L. (2017) · Pharmacopsychiatry · doi:10.1055/s-0043-120268 · Cited by 56
Role of nitric oxide in obsessive–compulsive behavior and its involvement in the anti-compulsive effect of paroxetine in mice
Umathe, S. N., Bhutada, P., Jain, N. S., Mundhada, Y. R., Borkar, S. S., & Dhumal, B. (2009) · Nitric Oxide · doi:10.1016/j.niox.2009.07.001 · Cited by 54
Comorbid Obsessive-Compulsive Symptoms in Schizophrenia: Insight into Pathomechanisms Facilitates Treatment
Zink, M. (2014) · Advances in Medicine · doi:10.1155/2014/317980 · Cited by 55
Update on pathological skin picking
Grant, J. E., & Odlaug, B. L. (2009) · Current Psychiatry Reports · doi:10.1007/s11920-009-0041-x · Cited by 51
Selective C-H trifluoromethoxylation of (hetero)arenes as limiting reagent
Deng, Z., Zhao, M., Wang, F. Y., & Tang, P. (2020) · Nature Communications · doi:10.1038/s41467-020-16451-x · Cited by 53

Authors: Coric, V., Taskiran, S., Pittenger, C., Wasylink, S., Mathalon, D. H., Valentine, G., Saksa, J., Wu, Y.-T., Gueorguieva, R., Sanacora, G., Malison, R. T., & Krystal, J. H.
Affiliations: Yale University (US)
ORCID: Taskiran, Sarper
Pittenger, Christopher
Mathalon, Daniel H.
Valentine, Gerald
Wu, Yu-te
Gueorguieva, Ralitza
Sanacora, Gerard
Malison, Robert T.
Krystal, John H.
Venue: Biological Psychiatry
Publisher: Elsevier BV
Published: 2005-09
Volume: 58
Issue: 5
Pages: 424-428
ISSN: 0006-3223 (ISSN-L)
DOI: 10.1016/j.biopsych.2005.04.043
OpenAlex: W1982538263
Cited by: 314
References: 25
Citations by year: 2026: 7 · 2025: 4 · 2024: 8 · 2023: 4 · 2022: 4 · 2021: 10 · 2020: 8 · 2019: 12 · 2018: 5 · 2017: 15 · 2016: 15 · 2015: 21 · 2014: 21 · 2013: 22 · 2012: 23
FWCI: 25.07
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Biological Psychiatry (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (5k05aa014906-03)
National Institute on Alcohol Abuse and Alcoholism (K05 AA 14906-01)
National Center for Research Resources (M01RR000125, M01 RR-00125)
Topics: Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
Social Sciences › Psychology › Clinical Psychology › Psychoanalysis and Psychopathology Research
Keywords: riluzole, treatment-resistant OCD, augmentation therapy, glutamate modulation, glutamatergic dysfunction, corticostriatal pathway, antidepressant effects, anxiolytic effects, adverse effects
MeSH terms: Adult, Drug Resistance, Female, Humans, Male, Middle Aged, Obsessive-Compulsive Disorder, Time Factors, Treatment Outcome, Excitatory Amino Acid Antagonists, Riluzole

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: An open-label trial

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks